NCT01275274撤回2 期
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- change in leukocyte Myeloperoxidase (MPO) and Proteinase 3 (PR3) message
研究概览
简要总结
The purpose of this research study is to learn if adding all-trans retinoic acid (tretinoin) to conventional treatment of Anti- Neutrophil Cytoplasmic Autoantibodies (ANCA) vasculitis can decrease the level of disease activity.
详细描述
Neutrophils are white blood cells that are the target of the ANCA antibodies. T cells are white blood cells that are involved in regulating the immune system. Laboratory research studies suggest that all-trans retinoic acid (tretinoin) can affect the neutrophils and the T lymphocytes in such a way that could decrease the abnormal immune response directed against the body own neutrophils.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with ANCA disease and no more than mild activity as determined by a BVAS score of 1 to
- •These are patients who will have undergone induction with cyclophosphamide and corticosteroids in the past, and will be in partial remission on maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. We anticipated that most patients enrolled in the study will have low grade persistent ("grumbling") disease on stable immunosuppressants.
- •Documented 6-fold or greater elevation in PR3 and/or MPO gene expression by the RT-PCR technique. We estimate that approximately 25% of patients with a BVAS <5 will have an elevation in PR3 and/or MPO gene expression based on our previous studies. 2 Patients must be on stable maintenance therapy with prednisone (<10 mg/day or equivalent), cyclosporine A, mycophenolate mofetil or azathioprine for at least 8 weeks.
排除标准
- •Patients with severe, active vasculitis requiring institution or an increase in dose of corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil or any new immunosuppressive medication within the previous 8 weeks or at the time of enrollment.
- •Pregnancy, breastfeeding, or unwillingness to use at least two contraceptive methods (at least one of which must be primary, including tubal ligation, partner vasectomy, oral contraceptives, implanted contraceptives, and intrauterine device). The rationale is that retinoids are teratogenic and are excreted in breast milk. Contraceptive methods must be instituted at least 1 month before starting tretinoin and continued at least 1 month after stopping the medication.
- •History of hepatitis, cirrhosis or abnormal liver tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), Alkaline phosphatase, Gamma-glutamyl transpeptidase (GGT), total bilirubin, or prothrombin time; unless the abnormality is due to a specific hepatotoxic medication, AND the liver test levels are l< 2 times the upper limit of the normal AND normalize upon holding the offending drug.
- •Hypertriglyceridemia (>500 mg/dL) despite statin/fibrate therapy.
- •Any medical conditions requiring concurrent use of tetracycline, minocycline, or doxycycline, due to enhanced risk of increased intracranial pressure.
- •Any medical conditions requiring concurrent use of rifampin, phenobarbital, pentobarbital, ketoconazole, cimetidine, erythromycin, verapamil, diltiazem, vitamin A and antithrombotic agents (Tranexamic Acid, Aminocaproic Acid or Aprotinin)due to the potential for interactions with tretinoin therapy.
- •Presence of unstable cardiovascular disease, uncontrolled diabetes with hemoglobin A1c > 8% g/dL, or chronic inflammatory or infectious conditions.
- •Glomerular Filtration Rate (GFR) <25 ml/min/1.73m^2 as estimated by the MDRD equation, as the metabolites of retinoids are excreted in part in urine, and there is a concern for increased toxicity.
- •Untreated depression, as retinoids have been associated with depression, suicidal ideation, and aggressive behavior.
- •Neutropenia (neutrophil count < 1000 cell/mm^3).
- •Known osteoporosis.
研究组 & 干预措施
Standard of care
Active Comparator
maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
干预措施: Standard of care (Drug)
Retinoic acid
Experimental
Tretinoin in addition to standard of care
干预措施: Retinoic acid (Drug)
结局指标
主要结局
change in leukocyte Myeloperoxidase (MPO) and Proteinase 3 (PR3) message
时间窗: week 12
normalization of PR3 and MPO message at the end of treatment.
次要结局
- Birmingham Vasculitis Activity Score (BVAS)(52 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Acute Myelogenous LeukemiaMyelodysplastic SyndromeNCT00136461Dana-Farber Cancer Institute40
已完成
2 期
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged SkinSkin AgingPurpuraNCT00272610University of Michigan50
已完成
3 期
Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and ModerateAcne VulgarisNCT00838812Igefarma Laboratorios S.A.154
进行中（未招募）
2 期
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)ANCA Associated VasculitisCardiovascular DiseasesKidney DiseasesNCT05630612University of Edinburgh32
撤回
3 期
ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)Acute Myeloid LeukemiaNCT01067274Acute Leukemia French Association